Strategies of nanomedicine for targeting the signaling pathways of Colorectal cancer

Colorectal cancer (CRC), is an emerging cause of cancer-related mortalities globally, results from the buildup of numerous genetic and epigenetic variations in the normal colonic and rectum epithelium, foremost to the advance from colorectal adenomas to aggressive malignant. In developed nations, there is a 5% probability of developing CRC. However, advanced CRC has a higher mortality rate. When the condition is localized, treatment success rates range from 70 to 90%. There is increasing evidence that the upkeep of multidrug resistance in CRC is influenced heavily by signaling pathways that regulate cell survival and drug metabolism. Consequently, abundant efforts have been carried out to target the signaling pathways to develop novel therapeutic approaches Nanotechnology has the potential to revolutionize cancer therapy. The major goal of drug delivery systems is to alleviate the negative risks of chemotherapeutics and simultaneously boost the efficacy of the treatment. Nano-medicines, despite their numerous benefits, encounter a variety of problems and barriers once they've been utilized to treat cancers effectively. In this review, we provide an outline of the risk factors, alteration in signaling pathways, particularly in CRC, and how delivery of nanomedicine mechanisms could be used for the successful treatment of tumors and metastasis in CRC. [Display omitted]